Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22422641 | 0.85 | MAPT (0.54) | HRH3 | |
| SCHEMBL7768079 | 0.83 | HRH3 (0.84) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL1206283 | 0.83 | HRH3 (0.64) | HRH3BCHE | |
| SCHEMBL7317159 | 0.81 | HDAC6 (0.47) | HRH3HDAC8HDAC6BCHE | |
| SCHEMBL13811533 | 0.79 | KCNH2 (0.41) | HRH3 | |
| SCHEMBL28629479 | 0.78 | HRH3 (0.55) | HRH3HDAC8HDAC6BCHEACHE | |
| SCHEMBL9970753 | 0.77 | HRH3 (0.58) | HRH3HDAC6 | |
| SCHEMBL12680476 | 0.77 | HRH3 (1.00) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL5926009 | 0.77 | HRH3 (0.73) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL8401340 | 0.76 | HRH3 (0.53) | HRH3HDAC8HDAC6BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531668-B2 | 2-arylcarboxamide-nitrogenous heterocycle compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070299070-A1 | 2-Arylcarboxamide-Nitrogenous Heterocycle Compound | MSD K.K. (JP) | 2007-12-27 | — | — | US | disclosed |
| CN-101065356-A | 2-arylcarboxamide-nitrogen-containing heterocyclic compounds | BANYU PHARMA CO LTD (JP) | 2007-10-31 | — | — | CN | disclosed |
| EP-1798221-A1 | 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299070-A1 | 2-Arylcarboxamide-Nitrogenous Heterocycle Compound | MCHR2, MCHR1, NPY2R | HRH3 98/4885HDAC8 1061/4885HDAC6 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.